Anthem Biosciences Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025 (Q3FY26 and 9MFY26). For the nine months ended December 31, 2025, the consolidated revenue from operations stood at ₹15,134 million (₹1513.4 crore), with EBITDA at ₹6,712 million (₹671.2 crore) and PAT at ₹4,020 million (₹402.0 crore), resulting in PAT margins of 24.8%. The CRDMO business contributed ₹12,599 million (₹1259.9 crore) and Specialty Ingredients contributed ₹2,535 million (₹253.5 crore) to the revenue. For the third quarter ended December 31, 2025, consolidated revenue from operations was ₹4,232 million (₹423.2 crore), with EBITDA at ₹1,907 million (₹190.7 crore) and PAT at ₹928 million (₹92.8 crore), reflecting PAT margins of 20.3%. The CRDMO business generated ₹3,332 million (₹333.2 crore) and Specialty Ingredients generated ₹899 million (₹89.9 crore) in revenue for the quarter. EBITDA margins for the quarter were 41.8%. An exceptional item of ₹254 million was recorded related to the impact of new labor codes. Ajay Bhardwaj, Chairman, MD and CEO, commented that the 9MFY26 performance showed steady progress in revenue and improving margin profile, with EBITDA growing at 23% and PBT before exceptional items growing around 20%. He noted that while quarterly revenue was influenced by a higher base from the previous year, margin improvement compensated for the revenue shortfall. The company is confident of a strong finish to the financial year, with its historically strongest quarter ahead. Anthem Biosciences Limited will hold an earnings call on February 5, 2026, at 2:30 PM IST to discuss its financial and business performance. The company has a net cash position of ₹12,312 million as of December 31, 2025.
